Should we start measuring lipids from now, year 2016?

Ever since in the year 2013, American guidelines focused on atherosclerotic cardiovascular disease as a prime focus for treating lipids. Measuring lipids in patients became a less important. More than that clinicians had only statins at their disposal for treating
Read the rest

Neprilysin Inhibitors, HFrEF and 2016 heart failure. Guidelines

Recently i.e. year 2016 both American and European guidelines have recommended combination of Neprilysin inhibitor with ARB i.e. LCZ696 (Sacubitril/valsartan) for treatment of heart failure with reduced ejection fraction(HFrEF)1,2. Landmark trial PARADIGM-HF was prematurely terminated due to significant
Read the rest

Azilsartan newer ARB, is it pleiotropic?

 Nowadays in pharma industry pleiotropic effect has become a trend. New molecules come with feather stating they have special extra advantage over previous class counterparts. Newer Angiotensin receptor blockers are being added to their group day by day. In
Read the rest

Game behind, premature termination of Random Control trials for extraordinary benefits.

These days increasing number of clinical trials (RCT) are terminated prematurely for claim of extraordinary benefit of experimental drug, procedure or investigation. Such prematurely terminated trials usually are published in high impact journal and get immediate recognation and acceptance of
Read the rest

Why treating stage 1 hypertension has no benefit?

It is very puzzling for most of us why stage1 hypertension has not shown reduction of CV events.  Stage 1 hypertension is 140-159/ 90-99 mmHg.
The results from Lewington et al meta-analysis, have shown that the cardiovascular mortality doubles from
Read the rest

Impact of bifurcation angle on stenting outcome.

Bifurcation angle in bifurcation stenting is widely debated subject there seems wide disparity among different trials some saying there is no impact of by bifurcation angle while some say distal bifurcation angle wider is bad while others say narrow is

Read the rest

Is Ventricular reshaping surgery back: CONFIGURE-HF stitched ventricle better than STICHED trial.

In STICHED trial benefit of ventricular reshaping surgery in heart failure along with CABG did not show benefit than just CABG. But CONFIGURE –HF Phase -1 trial presented recently in Heart Failure Congress 2013 showed benefit of ventricular reshaping surgery.

Read the rest